Skip to main content
Premium Trial:

Request an Annual Quote

Bluebee, Convey Ink Distribution Deal

NEW YORK (GenomeWeb) – Next-generation sequencing data analytics firm Bluebee and hybrid-core computing company Convey Computer today announced a distribution agreement.

Under the terms of the agreement, Convey can resell the Bluebee Genomics Analytics solution, while Bluebee will be able to incorporate the existing Convey bioinformatics components into its computer-based tools for whole-genome diagnostics.

Bluebee is extending its product portfolio to include an accelerated BWA MEM algorithm for long query read alignments. It also will offer a variant calling module on Convey's hybrid-core server architecture. The new solutions, the firms said, will allow geneticists to get more information more quickly.

Convey's bioinformatics offerings consist of components, such as the Convey GraphConstructor for de novo short-read assembly, as well as the Smith-Waterman algorithm for local sequence alignment, and the Burrows-Wheeler Aligner program for fast reference mapping.

Financial and other terms of the deal were not disclosed.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.